239 related articles for article (PubMed ID: 2533159)
41. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Collette L; Studer UE; Schröder FH; Denis LJ; Sylvester RJ
Prostate; 2001 Jun; 48(1):29-39. PubMed ID: 11391684
[TBL] [Abstract][Full Text] [Related]
42. Androgen blockade in prostate cancer.
Labrie F; Candas B
Lancet; 2000 Jul; 356(9226):341-2. PubMed ID: 11071217
[No Abstract] [Full Text] [Related]
43. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
[TBL] [Abstract][Full Text] [Related]
44. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
[TBL] [Abstract][Full Text] [Related]
45. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
Habenicht UF; Schröder H; el Etreby MF; Neumann F
Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
[No Abstract] [Full Text] [Related]
46. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Iversen P; Melezinek I; Schmidt A
BJU Int; 2001 Jan; 87(1):47-56. PubMed ID: 11121992
[No Abstract] [Full Text] [Related]
47. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer.
Tyrrell CJ
Prostate Suppl; 1992; 4():97-104. PubMed ID: 1574464
[TBL] [Abstract][Full Text] [Related]
48. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
Akaza H
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
[TBL] [Abstract][Full Text] [Related]
49. Estimated potency of Casodex: a problematic design.
Labrie F; Simard J; Singh SM; Candas B
Urology; 1997 Aug; 50(2):309-13. PubMed ID: 9255312
[No Abstract] [Full Text] [Related]
50. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
51. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
Tyrrell CJ
Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
[TBL] [Abstract][Full Text] [Related]
52. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
53. Bicalutamide (Casodex) in the treatment of prostate cancer.
Fradet Y
Expert Rev Anticancer Ther; 2004 Feb; 4(1):37-48. PubMed ID: 14748655
[TBL] [Abstract][Full Text] [Related]
54. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
55. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
[TBL] [Abstract][Full Text] [Related]
56. Current clinical studies with a new nonsteroidal antiandrogen, Casodex.
Kaisary AV
Prostate Suppl; 1994; 5():27-33. PubMed ID: 8172713
[TBL] [Abstract][Full Text] [Related]
57. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
Sogani PC; Whitmore WF
Cancer Treat Res; 1988; 39():131-45. PubMed ID: 2908604
[TBL] [Abstract][Full Text] [Related]
58. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Akakura K; Furuya Y; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
[TBL] [Abstract][Full Text] [Related]
59. Monotherapy in advanced prostate cancer: an overview.
Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
[TBL] [Abstract][Full Text] [Related]
60. Effects of two non-steroidal antiandrogens on testicular function in prepubertal rats.
Rulli SB; Gonzalez-Calvar SI; Campo S; Calandra RS
J Androl; 1995; 16(3):225-32. PubMed ID: 7559155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
